Clicking the "View this Article" button will open the issue as a resizable PDF. To take the test for
the issue, return to this Introduction page and click the "Take the Test" button. The Introduction
page will remain open after you open this issue.
You may need to re-size or close the issue in order to see the Introduction page.
The latest issue of The Rx Consultant is a primer for the 2018 ACC-AHA Cholesterol Management guideline for patients with high cholesterol. It summarizes new recommendations and includes a broader, more comprehensive approach to patient management. An estimated 56 million people in the US over the age of 40 years old have an indication for statin therapy.
The new guideline stresses atherosclerotic cardiovascular disease (ASCVD) risk reduction strategies, including those for special populations such as children/adolescents, older adults, women, certain ethnic groups, and patients with chronic kidney disease, inflammatory disorders, HIV, or elevated triglycerides. Patients with high cholesterol need to know their ASCVD risk - and they need advice about lifestyle changes that can reduce this risk, appropriate doses of statins, and counseling regarding statin side effects.
Cardiovascular disease (CVD), which includes high blood pressure, stroke, heart failure, and coronary heart disease, is prevalent and costly. Coronary heart disease is the most common form, accounting for 43% of all deaths attributed to CVD. The underlying pathophysiology of CVD is atherosclerosis; hence the term atherosclerotic cardiovascular disease (ASCVD). Risk factor management and treatment are essential to prevent CVD progression, cardiovascular events, and costly healthcare. It is important for both prescribers and pharmacists to educate patients about a heart healthy lifestyle and promote adherence to drug therapy to prevent disease progression and lower the costs associated with CVD.
In November 2018, the American College of Cardiology and the American Heart Association (ACC/AHA) cholesterol guideline was published online. The writing committee included physicians from several specialty areas, pharmacists, a nurse practitioner, a physician assistant, and a layperson. In addition to the ACC/AHA, the writing committee included representatives from 10 other national organizations. The guideline provides an evidence-based and patient-centered approach to the assessment and treatment of ASCVD. The 2018 guideline builds on many of the concepts introduced in the 2013 ACC/AHA cholesterol guideline, including the emphasis on using a high- or moderate-intensity statin as first-line therapy based on patient risk, the use of the 10-year ASCVD risk estimator for certain patients (Figure 1), measuring lipids to monitor response to therapy and adherence, and the patient-clinician discussion...
This program was developed by The Rx Consultant and published by Continuing Education Network, Inc. The Rx Consultant accepts no advertising or financial support from the pharmaceutical industry and is funded solely by the purchase of programs. The Rx Consultant is dedicated to providing unbiased, balanced information to health care practitioners.
Programs developed by The Rx Consultant are written by health care providers with expertise in the topic area, peer-reviewed, extensively edited, and fact-checked. This development process was created to insure that every program presents information that is current, accurate, relevant to "real world" health care providers, and written in an easy reading, "plain English" style.
The Rx Consultant is a publication of Continuing Education Network, Inc.
ACPE Universal Activity Number: 0428-0000-19-007-H01
Chief Editor and CE Administrator
Terry M. Baker, PharmD
Tracy Farnen, PharmD
James Chan, PharmD, PhD
Pharmacy Quality and Outcomes Coordinator
Associate Clinical Professor
Richard Ron Finley, B.S. Pharm.,R.Ph.
Consult Pharmacist Aging and Adult Health Services
Julio R. Lopez, PharmD, FCSHP
Adjunct Clinical Professor
Assistant Clinical Professor
Visiting Associate Professor and Lecturer
Pamela Mausner, MD
Helen Berlie, Pharm.D. CDE, BCACP
Ambulatory Care Specialist - Diabetes
Senior Editorial Advisor
Gerard Hatheway, PharmD, PhD
Belinda M. Danielson, RPh
Christopher M. DeSoto, PharmD
Angie S. Graham, PharmD
Cynthia Chan Huang, PharmD, MBA
Fred Plageman, PharmD
Editorial Advisor and Clinical Practice Consultant for Nurse Practitioners
Meuleman, RN, C, MS
Any hardware that supports Microsoft Windows, Apple Mac OS, iOS, or Android, and meets the software requirements.
Browser that supports TLS 1.1 + and PDF files.
This includes Microsoft Internet Explorer 11, Google Chrome 38, Google Android OS 5.0 Browser, Apple Safari (version 7 for desktop, 5 for mobile), Mozilla Firefox 27, newer versions of these browsers, as well as some earlier versions that may require additional configuration.
Adobe Acrobat Reader is recommended, and is required for some browsers.
Note: TLS 1.1 and 1.2 support is required for browser security. Click here for TLS browser support details.
Required. Broadband recommended. (T1, DSL, Cable, G4 or higher.)